Corporate – InfectoPharm participated with its best-selling product Fomicyt/Infectofos (IV Fosfomycin) at the two most important congresses in intensive care medicine (ISICEM 2023) and clinical infectiology (ECCMID 2023) in Europe and worldwide. Due to the rising threat of bacterial resistance globally, our product with its unique characteristics receives more and more attention. We expect it to make a real difference when dealing with difficult-to-treat infections in the years to come.
IV Fosfomycin with its InfectoPharm brands Fomicyt, InfectoFos, Fosfomycin InfectoPharm and IVOZFO is already used in more than 20 countries in and outside Europe (and many more to come) for patients with difficult-to-treat bacterial infections on intensive care and normal wards in daily clinical practice. Therefore, our customers represent both intensive physicians and infectious disease specialists in all countries where our product has been licensed and is used for treatment of patients with life-threatening bacterial infections.
The 42nd International Symposium on Intensive Care & Emergency Medicine took place from March 21–24th in Brussels, Belgium and attracted more than 6.000 on-site participants, mainly intensive-care physicians from all over the world. InfectoPharm contributed with a 15 m2 exhibition booth and sponsored a satellite symposium within the scientific program with title “Intravenous Fosfomycin: comprehensive new data evaluation for this WHO essential antibiotic for treatment of patients with severe infections in the ICU”. Our speakers were two internationally renown intensive care physicians/infectious disease specialists from Greece and Germany.
The second congress was the 33rd European Congress of Clinical Microbiology and Infectious Diseases that attracted more than 12.000 on site participants – mainly infectious disease specialists and clinical microbiologists from all over the world – on April 15–18th in Copenhagen, Denmark. We had a 48 m2 booth in central location and were supported by many of our partners, e. g. from Italy, Poland and Romania among many others.
Both congresses showed that for our brands Fomicyt, Infectofos, Fosfomycin Infectopharm and IVOZFO a worldwide high medical need does exist.
Additionally, in countries where the respective product has either not yet been launched or is still in registration process, physicians are eagerly waiting for new effective and safe therapeutic options for antibiotic treatment of patients with severe bacterial infections such as IV Fosfomycin.